Autopsy report · NCT04629781

Open-label Dose Escalation Phase 1b Trial of a New Micellar Docetaxel Compound in Patients With mCRPC

Cause of deathOther Automatic label, confidence 0.3, unverified. How labels are made.

“SAKK decided to premature terminate this trial as additional follow-up visits do not further contribute to the efficacy data. This decision does not adversely impact the patients.”

The sponsor’s own words in the registry.

Life of this trial

Registered 7 months before it started.
Ran for about 2 years 8 months before it stopped.
11 participants enrolled.
No results are posted on the registry.

Vital statistics

Status: Terminated
Phase: Phase 1
Sponsor: Swiss Cancer Institute
Sponsor type: University, hospital or other
Conditions: Metastatic Castration-resistant Prostate Cancer
Interventions: Docetaxel micellar
Participants: 11
Sites: 3
Countries: Switzerland

Look deeper

The official registry record (the source of truth)
Record history: every change the sponsor made
Open it in the database

Everything here comes from the current ClinicalTrials.gov record. The timeline uses the record’s dates; dates marked planned are the sponsor’s plans. The cause of death is an automatic, unverified label. This is research information, not medical advice.